v3.23.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:        
Revenue $ 657,778 $ 50,981 $ 1,423,678 $ 263,399
Operating expenses:        
Cost of revenues 383,691   995,431  
Research and development 5,732,961 4,726,517 12,728,809 8,659,864
Selling, general and administrative 7,393,197 4,890,544 14,213,747 8,667,167
Amortization of intangible asset 363,750 350,000 727,500 350,000
Change in fair value of contingent consideration 1,100,000 (203,000) 109,500 (224,000)
Total operating expenses 14,973,599 9,764,061 28,774,987 17,453,031
Loss from operations (14,315,821) (9,713,080) (27,351,309) (17,189,632)
Change in fair value of warrant liability   1,511   9,290
Interest (loss) income (191,000) 42,697 (139,969) 158,265
Unrealized (loss) gain on available-for-sale securities (26,001) (595,038) 63,321 (1,431,631)
Total non-operating loss (217,001) (550,830) (76,648) (1,264,076)
Net loss before income taxes (14,532,822) (10,263,910) (27,427,957) (18,453,708)
Income tax benefit 571,120 3,326,000 571,120 3,326,000
Net loss (13,961,702) (6,937,910) (26,856,837) (15,127,708)
Net loss - non-controlling interest (69,686) (106,624) (180,175) (175,835)
Net loss attributable to NightHawk Biosciences, Inc. $ (13,892,016) $ (6,831,286) $ (26,676,662) $ (14,951,873)
Net loss per share, basic (in dollars per share) $ (0.53) $ (0.27) $ (1.03) $ (0.58)
Net loss per share, diluted (in dollars per share) $ (0.53) $ (0.27) $ (1.03) $ (0.58)
Weighted-average common shares outstanding, basic (in shares) 26,047,591 25,602,965 26,009,578 25,598,481
Weighted-average common shares outstanding, diluted (in shares) 26,047,591 25,602,965 26,009,578 25,598,481
Comprehensive loss:        
Net loss $ (13,961,702) $ (6,937,910) $ (26,856,837) $ (15,127,708)
Unrealized gain on foreign currency translation 21,075 149,855 53,038 94,586
Total comprehensive loss (13,940,627) (6,788,055) (26,803,799) (15,033,122)
Comprehensive loss attributable to non-controlling interest (69,686) (106,624) (180,175) (175,835)
Comprehensive loss - NightHawk Biosciences, Inc. $ (13,870,941) $ (6,681,431) $ (26,623,624) $ (14,857,287)

Source